Contrast-Associated Nephropathy Risk Evaluation in Acute Ischemic Stroke After Endovascular Thrombectomy

NCT06596603 | Completed

• 1 other identifier: 4658_17.04.2024_N
• Study Type: observational
• Target: 8,000
• Locations: 1 country
• Sites: 1

Brief Summary

The CAN-REST study is a multicenter, observational, and retrospective study aimed at evaluating the incidence and risk factors of contrast-associated acute kidney injury (CA-AKI) in patients with acute ischemic stroke (AIS) who undergo endovascular thrombectomy (EVT). This study is conducted across multiple centers in Italy, Europe, the USA, and Canada, and includes data from AIS patients treated with EVT in 2023. The primary objectives are to assess the incidence of CA-AKI in this population and identify associated risk factors. Secondary objectives include evaluating the impact of CA-AKI on clinical outcomes, such as the length of hospital stay, functional recovery, and 90-day mortality, as well as developing risk stratification tools to predict CA-AKI. By analyzing a large cohort of patients, CAN-REST aims to provide critical insights into the renal complications associated with EVT and establish predictive models that can guide clinical decision-making and improve patient outcomes.

Conditions

Contrast-Associated Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

• Incidence of Contrast-Associated Acute Kidney Injury (CA-AKI)

  Measure the occurrence of acute kidney injury characterized by an increase in serum creatinine ≥0.3 mg/dL or ≥50% within 48 hours, or an increase of ≥0.3 mg/dL within 7 days post-endovascular thrombectomy in acute ischemic stroke patients.

  Within 48 hours and up to 7 days post-endovascular thrombectomy.

Secondary Outcomes (4)

• Days of In-Hospital Stay

  Measured daily from hospital admission until the day of discharge post-endovascular thrombectomy, assessed up to 30 days

• Functional Recovery (modified Rankin Scale, mRS; ranging from 0 [full recovery] to 6[death])

  90 days post-procedure

• All-Cause Mortality at 90 Days (modified Rankin Scale, mRS = 6)

  90 days post-procedure

• Development of Risk Stratification Tools

  24 hours, 48 hours, at 3 months, and at 12 months post-endovascular thrombectomy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All consecutive EVT-treated acute ischemic stroke patients discharged at the participating centers from 1 January 2023 to 31 December 2023.

To be eligible to participate in this study, subjects must meet all of the following criteria: * Age \>18 years at the time of AIS * Documented serum creatinine: * pre-EVT and * within 48h and/or within 7 days after EVT. Patients on chronic dialysis will be collected but excluded from the analyses

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Niguarda Hospital: lead

Study Sites (1)

ASST Grande Ospedale Metropolitano Niguarda

Milan, Lombardy, 20162, Italy

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2024
• First Posted: September 19, 2024
• Study Start: March 1, 2023
• Primary Completion: December 31, 2024
• Study Completion: July 1, 2025
• Last Updated: July 30, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)